Emerging Epigenetic Biomarkers Enhance Prediction of Cardiovascular Disease Risk
New epigenetic biomarkers identified in recent research could revolutionize cardiovascular disease risk prediction and early diagnosis, offering personalized approaches to prevention and treatment.
Recent research has identified over 100 novel epigenetic biomarkers that could significantly improve the prediction of cardiovascular disease (CVD) risk. Published in Circulation, this study indicates that these biomarkers, which are chemical modifications on DNA known as methylation marks, can provide insights into an individual’s cardiovascular health status. The discovery stems from an extensive analysis involving more than 10,000 participants across diverse cohorts, including the CARDIA, Framingham Heart, and MESA studies.
Building on previous findings that long-term cardiovascular health leaves detectable epigenetic signatures, researchers explored whether these markers could serve as early indicators of disease and mortality risk. They analyzed over 440,000 DNA methylation sites and identified 609 markers strongly associated with cardiovascular health, with 141 potentially playing a causal role in conditions such as stroke, heart failure, and gestational hypertension.
Importantly, the study found that these epigenetic markers could independently predict future cardiovascular events and mortality, beyond traditional risk factors like blood pressure and cholesterol. Individuals with favorable methylation profiles experienced up to 32% lower risk of developing cardiovascular disease, along with reduced mortality rates.
The findings suggest that routine blood tests assessing DNA methylation could offer a comprehensive view of a person’s health history, enabling earlier and more precise preventive interventions. The research team emphasizes the potential to integrate these biomarkers into clinical practice, possibly through developing cost-effective blood tests suitable for primary care. Such advancements promise to refine risk stratification and promote personalized healthcare strategies.
This groundbreaking work enhances our understanding of how lifestyle and health behaviors influence biological aging and disease risk. Moving forward, the team aims to collaborate with biotech firms to translate these findings into practical diagnostic tools, ultimately improving cardiovascular health outcomes across populations.
source: https://medicalxpress.com/news/2025-09-biomarkers-cardiovascular-disease.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Advancements in AI Enhance Precision and Speed in Lung Tumor Monitoring
Cutting-edge AI software is revolutionizing lung tumor detection by offering faster, more accurate comparison of CT scans—improving diagnosis and patient care.
Immune System Aging as a Potential Cause of Rheumatoid Arthritis
New research suggests that immune system aging may be a key factor in the development of rheumatoid arthritis, opening avenues for early prediction and preventative treatments.
Implementing Road Emission Policies Could Save 1.9 Million Lives by 2040
Strategic policies targeting road transport emissions could save 1.9 million lives and prevent millions of asthma cases globally by 2040. Implementing vehicle standards and promoting clean electric transportation are key to improving public health worldwide.
Native American Communities Face Medicaid Enrollment Challenges Amid New Work Requirements
Native American communities are at risk of healthcare coverage disruptions as new Medicaid work and eligibility requirements are implemented, highlighting ongoing procedural challenges and the importance of policy vigilance.